双参数MRI检测临床显著性前列腺癌:系统评价与Meta分析
该系统评价与Meta分析纳入17项研究共3964例患者,评估双参数MRI(bpMRI)检测临床显著性前列腺癌(csPCa)的诊断准确性。汇总敏感度为0.83(95%CI 0.76-0.88),特异度为0.71(95%CI 0.63-0.79),SROC曲线下面积为0.84(95%CI 0.81-0.87)。作者认为结果证实bpMRI检测csPCa及减少采集时间、患者不适和成本的可行性,但纳入研究存在异质性,需更稳健的验证及采集与报告标准化。
要点
- 双参数MRI检测临床显著性前列腺癌的汇总敏感度为0.83(95%CI 0.76-0.88),特异度为0.71(95%CI 0.63-0.79)。
- 汇总SROC曲线下面积为0.84(95%CI 0.81-0.87),阳性似然比2.9(95%CI 2.3-3.7),阴性似然比0.24(95%CI 0.17-0.33)。
- 纳入研究整体质量存在异质性,提示需更稳健的验证及前列腺bpMRI采集与报告标准化。
诊断标准与关键数值
- 双参数MRI检测临床显著性前列腺癌的汇总敏感度为0.83(95%CI 0.76-0.88),特异度为0.71(95%CI 0.63-0.79)。
- 汇总阳性似然比为2.9(95%CI 2.3-3.7),阴性似然比为0.24(95%CI 0.17-0.33),诊断比值比为12(95%CI 8-19)。
- 汇总SROC曲线下面积为0.84(95%CI 0.81-0.87)。
局限性
- 纳入研究整体质量存在异质性。
- 需更稳健的验证及前列腺双参数MRI采集与报告标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to perform a systematic review and a meta-analysis of diagnostic accuracy studies that used biparametric MRI (bpMRI) for the detection of clinically significant prostate cancer (csPCa). MATERIALS AND METHODS. Multiple medical databases were systematically searched to identify articles using bpMRI for csPCa detection. Sensitivity, specificity, PPV, and NPV were calculated for each study after enough data were extracted to create a 2 × 2 contingency table. Risk of bias was assessed using the QUADAS-2 tool. Meta-analyses based on bivariate random-effects methods were used to calculate pooled sensitivity, specificity, and summary ROC (SROC) curves. A meta-regression analysis was performed to assess heterogeneity sources. RESULTS. A total of 17 studies (3964 patients) that adopted PI-RADS or other scoring systems were included. Sensitivity, specificity, positive likelihood ratio (LR), negative LR, and diagnostic odds ratio of bpMRI in the detection of csPCa were 0.83 (95% CI, 0.76-0.88), 0.71 (95% CI, 0.63-0.79), 2.9 (95% CI, 2.3-3.7), 0.24 (95% CI, 0.17-0.33), and 12 (95% CI, 8-19), respectively, with an area under the SROC curve of 0.84 (95% CI, 0.81-0.87). The overall quality of the included studies was heterogeneous. CONCLUSION. Our results confirm the feasibility of bpMRI for the detection of csPCa and for reducing acquisition time, patient discomfort, and costs. Nevertheless, the available studies proved to be heterogeneous, indicating a need for a more robust validation of this imaging protocol and a standardization of prostate bpMRI acquisition and reporting.
引用
- Cuocolo R, Verde F, Ponsiglione A, et al. Clinically Significant Prostate Cancer Detection With Biparametric MRI: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2021. PMID: 33502226. doi:10.2214/AJR.20.23219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。